公开(公告)号：US07419962B2

公开(公告)日：2008-09-02

申请号：US11295736

申请日：2005-12-06

申请人： Yat Sun Or ,  Datong Tang ,  Ying Sun ,  Yonghua Gai ,  Guoyou Xu ,  Zhe Wang

发明人： Yat Sun Or ,  Datong Tang ,  Ying Sun ,  Yonghua Gai ,  Guoyou Xu ,  Zhe Wang

IPC分类号： A61K31/70 ,  C07H17/08

CPC分类号： C07H17/08

摘要： The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

摘要翻译： 本发明公开了具有抗菌性质的式（I）化合物或其药学上可接受的盐，酯或前药。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

公开(公告)号：US20080125444A1

公开(公告)日：2008-05-29

申请号：US11758901

申请日：2007-06-06

申请人： Ying Sun ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K31/497 ,  A61K31/4015 ,  A61K31/4025 ,  C07D207/12 ,  C07D403/12 ,  C12N7/06 ,  C07D405/12 ,  C07D401/14 ,  A61P31/12 ,  A61K31/4375

CPC分类号： C07D207/12 ,  A61K38/00 ,  C07D207/16 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D471/04 ,  C07K5/0812

摘要： The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20070281884A1

公开(公告)日：2007-12-06

申请号：US11502740

申请日：2006-08-11

申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/12 ,  A61K31/395 ,  C07K5/12

CPC分类号： A61K38/212 ,  A61K38/12 ,  A61K38/215 ,  C07K5/0804 ,  A61K2300/00

摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US07273851B2

公开(公告)日：2007-09-25

申请号：US10849107

申请日：2004-05-19

申请人： Zhenwei Miao ,  Ying Sun ,  Suanne Nakajima ,  Datong Tang ,  Zhe Wang ,  Yat S. Or

发明人： Zhenwei Miao ,  Ying Sun ,  Suanne Nakajima ,  Datong Tang ,  Zhe Wang ,  Yat S. Or

IPC分类号： A61K38/00

CPC分类号： C07K5/0808 ,  A61K38/00

摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20070142384A1

公开(公告)日：2007-06-21

申请号：US10591214

申请日：2005-02-24

申请人： Michelle Akerman ,  Jonathan Houze ,  Daniel Lin ,  Jinqian Liu ,  Jiwen Liu ,  Jian Luo ,  Zhihua Ma ,  Julio Medina ,  Wei Qiu ,  Jeffrey Reagan ,  Rajiv Sharma ,  Michael Schmitt ,  Stephen Shuttleworth ,  Ying Sun ,  Yingcai Wang ,  Jian Zhang ,  Liusheng Zhu

发明人： Michelle Akerman ,  Jonathan Houze ,  Daniel Lin ,  Jinqian Liu ,  Jiwen Liu ,  Jian Luo ,  Zhihua Ma ,  Julio Medina ,  Wei Qiu ,  Jeffrey Reagan ,  Rajiv Sharma ,  Michael Schmitt ,  Stephen Shuttleworth ,  Ying Sun ,  Yingcai Wang ,  Jian Zhang ,  Liusheng Zhu

IPC分类号： A61K31/522 ,  A61K31/4965 ,  A61K31/52 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/4439 ,  A61K31/415

CPC分类号： C07D277/24 ,  C07D277/30

摘要： The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L1-P-L2-M-X-L3-A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.

摘要翻译： 本发明提供了可用于例如用于调节受试者中胰岛素水平的化合物，并且具有通式QL 1 -PL 2 -MXL 3 SUP> -A，其中变量Q，L 1，P，L 2，M，X，L 3和A的定义是 本文提供。 本发明还提供了用于治疗II型糖尿病的化合物的组合物和方法。

公开(公告)号：US07229972B2

公开(公告)日：2007-06-12

申请号：US11008581

申请日：2004-12-07

申请人： Yat Sun Or ,  Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Guoyou Xu ,  Zhe Wang

发明人： Yat Sun Or ,  Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Guoyou Xu ,  Zhe Wang

IPC分类号： A61K31/70 ,  C07H17/08

CPC分类号： C07H17/08

摘要： The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

摘要翻译： 本发明公开了具有抗菌性质的式（I）化合物或其药学上可接受的盐，酯或前药。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

公开(公告)号：US20070060510A1

公开(公告)日：2007-03-15

申请号：US11489011

申请日：2006-07-18

申请人： Suanne Nakajima ,  Zhenwei Miao ,  Ying Sun ,  Datong Tang ,  Guoyou Xu ,  Brian Porter ,  Yat Or ,  Zhe Wang

发明人： Suanne Nakajima ,  Zhenwei Miao ,  Ying Sun ,  Datong Tang ,  Guoyou Xu ,  Brian Porter ,  Yat Or ,  Zhe Wang

IPC分类号： A61K38/12 ,  A61K31/497 ,  C07K5/12 ,  C07D487/14

CPC分类号： C07K5/0802 ,  A61K38/212 ,  A61K38/215 ,  C07D487/04 ,  C07K5/0804 ,  A61K2300/00

摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20070049901A1

公开(公告)日：2007-03-01

申请号：US11409454

申请日：2006-04-21

申请人： Jeffrey Wu ,  Jue Liu ,  Ying Sun ,  Justin McDonough ,  Danilo Lambino ,  Mariam Maghribi

发明人： Jeffrey Wu ,  Jue Liu ,  Ying Sun ,  Justin McDonough ,  Danilo Lambino ,  Mariam Maghribi

IPC分类号： A61M31/00

CPC分类号： A61M37/0015 ,  A61B2017/00765 ,  A61M37/00 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61N1/306 ,  A61N1/325

摘要： The invention features a method of treating acne by piercing the stratum corneum of skin in need of such treatment with a stratum corneum-piercing device that contains at east one stratum corneum-piercing microprotrusion and a compressible cover such that the compressible cover substantially encases the at least one stratum corneum-piercing microprotrusion, and wherein upon contacting the skin with the compressible cover, the at least one stratum corneum-piercing microprotrusion protrudes from the compressible cover and pierces the stratum corneum of the skin.

摘要翻译： 本发明的特征在于一种通过用东方一角质层穿刺微灌注的角质层刺穿装置刺穿需要这种治疗的皮肤角质层来治疗痤疮的方法，使得可压缩盖基本上包围在 至少一个角质层刺穿微灌注，并且其中当使皮肤与可压缩覆盖层接触时，至少一个角质层刺穿的微量突出从可压缩盖突出并刺穿皮肤的角质层。

公开(公告)号：US20070014489A1

公开(公告)日：2007-01-18

申请号：US11365273

申请日：2006-03-01

申请人： Ying Sun ,  Gareth Funka-Lea

发明人： Ying Sun ,  Gareth Funka-Lea

IPC分类号： G06K9/32 ,  G06K9/00

CPC分类号： G06T7/20 ,  G06T7/0012 ,  G06T2207/30048

摘要： Motion of the heart during contrast enhancement is modeled at two hierarchical levels: global translation and local deformation. Large-scale, i.e., global, translational motion is identified using global template matching, while the local deformation of a portion of the object (e.g., the left ventricle where the object is a heart) is obtained using an adaptive local template matching scheme which adapts to the local edge distributions by varying the height and the width of the template as well as the location of the template followed by spatial regularization. To address the difficulty of rapid intensity changes across the image sequence as the contrast agent perfuse into the tissue, an edge-based similarity measure is used for template matching.

摘要翻译： 在对比度增强过程中心脏的运动被建模在两个层次上：全局平移和局部变形。 使用全局模板匹配来确定大规模，即全局，平移运动，而使用自适应局部模板匹配方案获得对象部分（例如，对象是心脏的左心室）的局部变形， 通过改变模板的高度和宽度以及模板的位置跟随空间正则化来适应局部边缘分布。 为了解决造影剂灌注到组织中的图像序列之间的快速强度变化的难度，使用基于边缘的相似性度量来进行模板匹配。

公开(公告)号：US07125845B2

公开(公告)日：2006-10-24

申请号：US10613206

申请日：2003-07-03

申请人： Frank X. H. Wu ,  Suanne Nakajima ,  Zhi-Hui Lu ,  Ying Sun ,  Zhenwei Miao ,  Yat Sun Or ,  Zhe Wang

发明人： Frank X. H. Wu ,  Suanne Nakajima ,  Zhi-Hui Lu ,  Ying Sun ,  Zhenwei Miao ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/00

CPC分类号： C07K5/06139 ,  A61K38/00 ,  C07K5/06165

摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。